HN2003000193A - Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age. - Google Patents

Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age.

Info

Publication number
HN2003000193A
HN2003000193A HN2003000193A HN2003000193A HN2003000193A HN 2003000193 A HN2003000193 A HN 2003000193A HN 2003000193 A HN2003000193 A HN 2003000193A HN 2003000193 A HN2003000193 A HN 2003000193A HN 2003000193 A HN2003000193 A HN 2003000193A
Authority
HN
Honduras
Prior art keywords
diseases
nephropatia
treatment
age associated
vasopeptidase inhibitors
Prior art date
Application number
HN2003000193A
Other languages
English (en)
Inventor
Sanofi Aventis Deutschland Gmbh
Original Assignee
Sanofi Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland Gmbh filed Critical Sanofi Aventis Deutschland Gmbh
Publication of HN2003000193A publication Critical patent/HN2003000193A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

LA PRESENTE INVENCION SE REFIERE A LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) ES UNA PEPTIDIL DIPEPTIDASA QUE CATALIZA LA CONVERSION DE ANGIOTENSINA I EN ANGIOTENSINA II.
HN2003000193A 2002-06-28 2003-06-26 Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age. HN2003000193A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2002129180 DE10229180A1 (de) 2002-06-28 2002-06-28 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen

Publications (1)

Publication Number Publication Date
HN2003000193A true HN2003000193A (es) 2004-10-27

Family

ID=29795983

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2003000193A HN2003000193A (es) 2002-06-28 2003-06-26 Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age.

Country Status (39)

Country Link
US (2) US6930103B2 (es)
EP (1) EP1519732B1 (es)
JP (1) JP4564354B2 (es)
KR (1) KR101072235B1 (es)
CN (1) CN100366254C (es)
AR (1) AR040343A1 (es)
AT (1) ATE548040T1 (es)
AU (1) AU2003280440B2 (es)
BR (1) BR0312250A (es)
CA (1) CA2490277C (es)
CR (1) CR7667A (es)
CY (1) CY1112905T1 (es)
DE (1) DE10229180A1 (es)
DK (1) DK1519732T3 (es)
EC (1) ECSP045513A (es)
ES (1) ES2383889T3 (es)
HK (1) HK1079435A1 (es)
HN (1) HN2003000193A (es)
HR (1) HRP20041212B1 (es)
IL (2) IL165935A0 (es)
MA (1) MA27281A1 (es)
MX (1) MXPA04012230A (es)
NO (1) NO334811B1 (es)
NZ (1) NZ537480A (es)
OA (1) OA12871A (es)
PA (1) PA8576501A1 (es)
PE (1) PE20040582A1 (es)
PL (1) PL218070B1 (es)
PT (1) PT1519732E (es)
RS (1) RS52478B (es)
RU (1) RU2336080C2 (es)
SI (1) SI1519732T1 (es)
SV (1) SV2004001560A (es)
TN (1) TNSN04262A1 (es)
TW (1) TWI326215B (es)
UA (1) UA82845C2 (es)
UY (1) UY27869A1 (es)
WO (1) WO2004002492A1 (es)
ZA (1) ZA200409382B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482546C2 (ru) * 2011-04-28 2013-05-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к с-концевому фрагменту рецептора ангиотензина ii

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
EP0589037B1 (en) * 1991-03-01 1996-05-29 Zeria Pharmaceutical Co., Ltd. Indian derivative and thromboxane antagonist containing the same
DE69220744T2 (de) * 1991-09-27 1997-11-13 Merrell Pharma Inc 2-Substituierte Indan-2-Mercaptoacetylamid-Verbindungen mit Enkephalinase und ACE-Hemmwirkung
WO1993016103A1 (en) * 1992-02-14 1993-08-19 Merrell Dow Pharmaceuticals Inc. Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
ES2141923T3 (es) * 1994-03-24 2000-04-01 Merrell Pharma Inc Uso hipocolesterolemico, antiaterosclerotico e hipotrigliceridemico de derivados aminoacetilmercapto.
WO1997002032A1 (en) * 1995-06-30 1997-01-23 Merck & Co., Inc. Method of treating renal disease using an ace inhibitor and an aii antagonist
DE69630465T2 (de) 1995-12-27 2004-07-22 Mitsubishi Pharma Corp. Vorsorge-/heilmittel fur die komplikationen von diabetes
UA77151C2 (en) * 1999-08-30 2006-11-15 Sanofi Aventis Deutschland Use of ramipril for prevention of cardiovascular events
US6149915A (en) 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
SI1381605T1 (en) * 2001-04-12 2005-06-30 Aventis Pharma Deutschland Gmbh Mercaptoacetylamide derivatives, a process for their preparation and their use
US20030040509A1 (en) * 2001-08-06 2003-02-27 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ACE

Also Published As

Publication number Publication date
TW200406214A (en) 2004-05-01
AU2003280440A1 (en) 2004-01-19
SV2004001560A (es) 2004-02-26
AU2003280440B2 (en) 2009-07-16
DK1519732T3 (da) 2012-06-18
TWI326215B (en) 2010-06-21
HRP20041212B1 (hr) 2013-06-30
ES2383889T3 (es) 2012-06-27
DE10229180A1 (de) 2004-01-29
CN100366254C (zh) 2008-02-06
EP1519732A1 (en) 2005-04-06
PT1519732E (pt) 2012-05-22
RS52478B (en) 2013-02-28
KR101072235B1 (ko) 2011-10-12
US20050171090A1 (en) 2005-08-04
TNSN04262A1 (en) 2007-03-12
JP4564354B2 (ja) 2010-10-20
NO334811B1 (no) 2014-06-02
MA27281A1 (fr) 2005-04-01
IL165935A (en) 2010-12-30
CN1665512A (zh) 2005-09-07
WO2004002492A1 (en) 2004-01-08
CR7667A (es) 2005-06-16
KR20050013642A (ko) 2005-02-04
PA8576501A1 (es) 2004-02-07
CA2490277C (en) 2011-11-01
NZ537480A (en) 2005-11-25
RU2336080C2 (ru) 2008-10-20
ZA200409382B (en) 2006-01-25
PL372992A1 (en) 2005-08-08
HK1079435A1 (en) 2006-04-07
RU2005102087A (ru) 2005-07-10
UY27869A1 (es) 2003-12-31
OA12871A (en) 2006-09-15
PL218070B1 (pl) 2014-10-31
HRP20041212A2 (en) 2005-06-30
US7514423B2 (en) 2009-04-07
US20040058911A1 (en) 2004-03-25
ECSP045513A (es) 2005-03-10
UA82845C2 (en) 2008-05-26
US6930103B2 (en) 2005-08-16
JP2005533815A (ja) 2005-11-10
BR0312250A (pt) 2005-04-26
EP1519732B1 (en) 2012-03-07
CA2490277A1 (en) 2004-01-08
NO20050425L (no) 2005-01-25
AR040343A1 (es) 2005-03-30
PE20040582A1 (es) 2004-10-18
IL165935A0 (en) 2006-01-15
CY1112905T1 (el) 2016-04-13
SI1519732T1 (sl) 2012-05-31
MXPA04012230A (es) 2005-02-25
ATE548040T1 (de) 2012-03-15
RS100704A (en) 2007-02-05

Similar Documents

Publication Publication Date Title
TW200505434A (en) Therapeutic treatment
CR11486A (es) Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
HN2003000227A (es) Inhibidores de quinasas
UA94221C2 (en) Lipocalin protein
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
ECSP045429A (es) Combinacion de compuestos organicos
EA201100506A1 (ru) Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
ATE312635T1 (de) Ventilanordnung
EP1740183B8 (en) Novel use for pde5 inhibitors
ECSP056173A (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
MXPA05006629A (es) Formas de dosificacion que contienen un inhibidor de bomba de protones, un nsaid y un amortiguador.
HN2003000247A (es) Combinaciones sinergicas
HRP20090513T1 (en) S-mirtazapine for the treatment of hot flush
HN2003000208A (es) Estructura perfeccionada de suela impermeable y transpirante para calzados
BR0306820A (pt) Uso de inibidores cox-2 em combinação com agentes antivirais para o tratamento de infecções de papilomavìrus
DE50308434D1 (de) Enzymatische herstellung urethangruppenhaltiger (meth)acrylsäureeester
MX2007002277A (es) Metodos para formar retinoides y usos de los mismos.
DE60013486D1 (de) Verbindungen
EP1546182A4 (en) COMPOSITIONS AND METHOD FOR DIAGNOSING AND TREATING TUMORS
BR0311191A (pt) Combinação
HN2003000193A (es) Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age.
ATE410448T1 (de) Neues peptid und pharmazeutische zusammensetzung, die dieses peptid enthält
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
NO20071330L (no) Enzyminhibitor i leukemi